Editorial Policy & Clinical Integrity
Last updated: May 26, 2026. Reviewed under KosPharm editorial standards.
1Primary Authoritative Data Sources
Every clinical monograph, therapeutic class, contraindication, and dosing parameter indexed within KosPharm is derived from authoritative, publicly validated datasets:
- United States FDA Database: Approved product labeling, post-marketing safety alerts, black box warnings, and application records.
- Mosby Clinical Standards: Structured pharmacological sections (action, pharmacokinetics, adverse reactions, nursing considerations).
- Peer-Reviewed Guidelines: Consensus recommendations from recognized clinical societies (e.g. KDIGO for renal dosing, ACC/AHA for cardiovascular pharmacotherapy).
2Strict Commercial Independence
Zero Commercial or Pharmaceutical Sponsorship
KosPharm maintains strict commercial independence. We do not accept advertising, paid drug placements, or promotional funding from pharmaceutical manufacturers. All drug monographs are indexed and presented neutrally by generic pharmacological naming.
3Calculator safety
Clinical tools, including creatinine clearance, body surface area, and interaction screening, use documented formulas and reference information. Review each result alongside the patient’s clinical context before making care decisions.
4Corrections & Continuous Maintenance
We review available regulatory updates and welcome reports of discrepancies, newly published warnings, or labeling changes at [email protected].